Gensia Sicor Gets FDA OK for Cancer Drug

Sicor Inc. said Monday that its Gensia Sicor Pharmaceuticals Inc. unit received Food and Drug Administration approval to sell a generic version of a drug that treats breast, ovarian and certain bladder carcinomas and various lymphomas.

The Irvine specialty pharmaceutical company said in a news release that the government approved the sale of its Thiotepa injectable drug.

Sicor stock lost 15 cents to close at $10.51 a share on Nasdaq.